Pentose phosphate pathway function affects tolerance to the G-quadruplex binder TMPyP4

Elizabeth J Andrew1, Stephanie Merchan, Conor Lawless

  • 1Institute for Cell and Molecular Biosciences, Newcastle University Medical School, Newcastle Upon Tyne, United Kingdom.

Plos One
|June 19, 2013
PubMed

Insights

The anti-cancer drug candidate TMPyP4 causes light-dependent oxidative stress in yeast, not G-quadruplex binding. This finding impacts the drug

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • G-quadruplexes are DNA structures found in guanine-rich regions, particularly at telomeres.
  • Ligands like TMPyP4 stabilize G-quadruplexes and are investigated as anti-cancer agents.
  • Understanding TMPyP4's in vivo mechanism is crucial for its therapeutic potential.

Purpose of the Study:

  • To elucidate the in vivo mechanism of action of the G-quadruplex ligand TMPyP4.
  • To identify cellular pathways involved in TMPyP4 sensitivity using a genome-wide screen in Saccharomyces cerevisiae.

Main Methods:

  • Conducted a genome-wide screen in budding yeast (Saccharomyces cerevisiae) to identify genes affecting TMPyP4 sensitivity.
  • Assessed sensitivity to TMPyP4, hydrogen peroxide, RHPS4, and hydroxyurea in gene deletion strains.
  • Investigated the role of the pentose phosphate pathway (PPP) and oxidative stress response genes (CCS1, YAP1).

Main Results:

  • Deletion of key pentose phosphate pathway (PPP) genes increased yeast sensitivity to TMPyP4.
  • Sensitivity to TMPyP4 was also elevated in strains lacking oxidative stress response genes (CCS1, YAP1).
  • TMPyP4-sensitive strains showed cross-sensitivity to hydrogen peroxide, suggesting a role for oxidative stress.

Conclusions:

  • TMPyP4 treatment induces a light-dependent oxidative stress response in budding yeast.
  • Oxidative stress, rather than direct G-quadruplex binding, appears to be the primary mechanism of TMPyP4 cytotoxicity.
  • Findings have significant implications for the therapeutic application and understanding of TMPyP4's mechanism of action.

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Proofreading01:43

Proofreading

Overview